Company
Lifescan
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4
510(k), De Novo and PMA
Device trials
16
As lead sponsor, any status
Adverse event reports
65
Received Nov 1, 2025 to Nov 20, 2026
Recall records
27
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Lifescan, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Lifescan.
Latest FDA decisions
K193475 · Decided Feb 14, 2020 · 60 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
K163357 · Decided Jun 7, 2017 · 189 days after receipt
Device type: Pump, Infusion, Insulin Bolus (OPP) · Hospital Medicine & Nursing
K151611 · Decided Dec 14, 2015 · 182 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06052371 · 99 participants · Start Oct 16, 2023 · Primary completion Dec 1, 2023
Device: VerioVue (Enhancements) blood glucose monitoring system · For: Diabetes Mellitus
Sites: London, United Kingdom; Manchester, United Kingdom · 3 sites in all
NCT06121856 · 116 participants · Start Feb 7, 2023 · Primary completion Apr 28, 2023
Device: VerioVue Enhancements BGMS · For: Diabetes Mellitus
Sites: Edinburgh, United Kingdom
- Evidence for Health Improvement in People With Diabetes Using One Touch & Partner SolutionsStatus unknown
NCT05354297 · 800 participants (planned) · Start Jul 26, 2022 · Primary completion Apr 1, 2023
Device: Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app; Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app and 2 more · For: Diabetes Mellitus, Type 2
Sites: San Mateo, California
13 more trials with a free account
Reports received
65
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
2
3.1% of reports
Injury reports
62
95% of reports
Death reports
1
1.5% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 4 | 36 | 0 | 0 |
| Jan 24 | 3 | 22 | 0 | 0 |
| Feb 24 | 0 | 31 | 0 | 0 |
| Mar 24 | 0 | 10 | 0 | 0 |
| Apr 24 | 0 | 16 | 0 | 0 |
| May 24 | 2 | 11 | 0 | 0 |
| Jun 24 | 0 | 17 | 0 | 0 |
| Jul 24 | 0 | 12 | 0 | 0 |
| Aug 24 | 0 | 14 | 0 | 0 |
| Sep 24 | 2 | 12 | 0 | 0 |
| Oct 24 | 1 | 15 | 0 | 0 |
| Nov 24 | 1 | 12 | 0 | 0 |
| Dec 24 | 0 | 6 | 0 | 0 |
| Jan 25 | 0 | 10 | 0 | 0 |
| Feb 25 | 0 | 8 | 0 | 0 |
| Mar 25 | 0 | 10 | 0 | 0 |
| Apr 25 | 0 | 10 | 0 | 0 |
| May 25 | 2 | 0 | 0 | 0 |
| Jun 25 | 0 | 8 | 0 | 0 |
| Jul 25 | 2 | 8 | 0 | 0 |
| Aug 25 | 1 | 6 | 0 | 0 |
| Sep 25 | 0 | 6 | 0 | 0 |
| Oct 25 | 0 | 8 | 0 | 0 |
| Nov 25 | 0 | 6 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 1 | 2 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 12 | 0 | 0 |
| Apr 26 | 1 | 6 | 1 | 0 |
| May 26 | 0 | 4 | 0 | 0 |
| Jun 26 | 0 | 8 | 0 | 0 |
| Jul 26 | 0 | 11 | 0 | 0 |
| Aug 26 | 0 | 3 | 0 | 0 |
| Sep 26 | 0 | 8 | 0 | 0 |
| Oct 26 | 0 | 2 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1074-2013 · Started Mar 11, 2013 · Posted by FDA Apr 12, 2013
Reason given: The Verio IQ meter will shut off and revert to set up mode at glucose values above 1023 instead of displaying EXTREME HIGH GLUCOSE.
Cause as FDA categorized it: Software design · Device type: System, Test, Blood Glucose, Over The Counter (NBW)
Z-1129-2013 · Started Feb 25, 2013 · Posted by FDA Apr 17, 2013
Reason given: When OneTouch Ultra and OneTouch Select test strips are tested with Ultra and Select control solution the meter may display a result outside the control solution test range printed on the strip vial label even though the system is working properly.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Single (Specified) Analyte Controls (Assayed And Unassayed) (JJX)
Z-1130-2013 · Started Feb 25, 2013 · Posted by FDA Apr 17, 2013
Reason given: When OneTouch Ultra and OneTouch Select test strips are tested with Ultra and Select control solution the meter may display a result outside the control solution test range printed on the strip vial label even though the system is working properly.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Single (Specified) Analyte Controls (Assayed And Unassayed) (JJX)
24 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.